Cargando…
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
PURPOSE OF REVIEW: There have been significant advances in the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) over the past two decades. However, the intention of treatment remains control of the disease and delay of progression rather than a cure which remains largely elusive....
Autores principales: | Odetola, Oluwatobi, Ma, Shuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242240/ https://www.ncbi.nlm.nih.gov/pubmed/37278884 http://dx.doi.org/10.1007/s11899-023-00700-z |
Ejemplares similares
-
Next-Generation Sequencing—Optimal Sequencing of Therapies in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Simon, Florian, et al.
Publicado: (2023) -
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
por: Aldapt, Mahmood B, et al.
Publicado: (2021) -
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
por: Van Den Neste, Eric, et al.
Publicado: (2012) -
Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008) -
Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022)